Sonoma Pharmaceuticals (SNOA) Current Deferred Revenue (2011 - 2026)
Sonoma Pharmaceuticals' (SNOA) quarterly Current Deferred Revenue came in at $284000.0 in Q1 2026, down 55.69% year-on-year from $641000.0 in Q1 2025, and up 91.89% quarter-over-quarter from $148000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Current Deferred Revenue (2011 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Current Deferred Revenue history runs 16 years deep, the most recent figure standing at $284000.0 for Q1 2026.
- On a quarterly basis, Current Deferred Revenue fell 55.69% year-over-year to $284000.0 in Q1 2026; TTM through Mar 2026 was $284000.0, a 55.69% decrease from a year earlier, with the FY2026 full-year figure at $284000.0, down 55.69% from the prior year.
- Current Deferred Revenue rose to $284000.0 in Q1 2026 per SNOA's latest filing, from $148000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $1.2 million in Q1 2022 and bottomed at $75000.0 in Q4 2023.
- The 5-year median for Current Deferred Revenue is $220000.0 (2024), against an average of $356000.0.
- Across the five-year window, Current Deferred Revenue soared 358.05% in 2022 and slumped 83.73% in 2023, its largest moves.
- Year by year, Current Deferred Revenue stood at $100000.0 in 2022, then decreased by 25.0% to $75000.0 in 2023, then surged by 302.67% to $302000.0 in 2024, then slumped by 50.99% to $148000.0 in 2025, then jumped by 91.89% to $284000.0 in 2026.
- Per Business Quant, the three latest SNOA Current Deferred Revenue figures stand at $284000.0 (Q1 2026), $148000.0 (Q4 2025), and $750000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 284,000.00 |
| Dec 31, 2025 | 148,000.00 |
| Sep 30, 2025 | 750,000.00 |
| Jun 30, 2025 | 731,000.00 |
| Mar 31, 2025 | 641,000.00 |
| Dec 31, 2024 | 302,000.00 |
| Sep 30, 2024 | 220,000.00 |
| Jun 30, 2024 | 413,000.00 |
| Mar 31, 2024 | 565,000.00 |
| Dec 31, 2023 | 75,000.00 |
| Sep 30, 2023 | 101,000.00 |
| Jun 30, 2023 | 100,000.00 |
| Mar 31, 2023 | 199,000.00 |
| Dec 31, 2022 | 100,000.00 |
| Sep 30, 2022 | 100,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Mar 31, 2022 | 1.22 Mn |
| Dec 31, 2021 | 100,000.00 |
| Sep 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 185,000.00 |